Kelly Paul Edward's Form 4 filing
Relmada Therapeutics, Inc. (RLMD) · filed May 20, 2025
- Accession no.
- 0001213900-25-046088
- Filed
- May 20, 2025, 6:03 PM ET
- Trade date
- May 16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $86.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kelly Paul EdwardCIK 0001658544 | Director, Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Stock | PPurchaseAcquired | +200,000 | $0.4303F2 | +$86,060 | 412,295 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Purchase prices range from $0.4071 to $0.4498 per share, inclusive.
Referenced by the price of 1 transaction in Table I.